article thumbnail

AI in Pharmaceuticals: From Discovery to Market

Complex Discovery

Editor’s Note: Artificial intelligence (AI) is transforming the pharmaceutical industry, offering unprecedented opportunities to accelerate drug discovery, streamline clinical trials, and fortify intellectual property (IP) strategies.

article thumbnail

Legal Turmoil in the Pharmaceutical Industry: AbbVie, Purdue, and Beyond

Complex Discovery

Editor’s Note: In a legal confrontation that could significantly impact the pharmaceutical industry, AbbVie has petitioned the U.S. Adding to the legal drama, the pharmaceutical industry faces challenges in Mississippi, where U.S. has petitioned the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Other Barks & Bites for Friday, March 7: Lashify Wins ITC Appeal on Economic Prong Analysis; CAFC Says Apple Did Not Violate Discovery Obligations at PTAB; and ParkerVision Files Reply Brief on Rule 36 Appeal at SCOTUS

IP Watchdog

International Trade Commissions economic prong analysis for the domestic industry requirement of Section 337, finding that petitioners at the Patent Trial and Appeal Board have no self-executing discovery obligations to present evidence from parallel ITC proceedings, and more; strong global demand for AI chips buoys Broadcoms first quarter results; (..)

article thumbnail

Five Great Reads on Cyber, Data, and Legal Discovery for July 2024

Complex Discovery

The publication selects five top articles to keep legal, business, and technology professionals informed about key developments in cyber discovery, data discovery, and legal discovery. This month’s “Top Five Reads” feature an array of topics crucial to professionals navigating these dynamic fields.

article thumbnail

Motion to Compel Plaintiff to Designate Additional Custodians Granted in Part

E-Discovery LLC

Teva Pharmaceutical Industries, Ltd., Based on the terms of an ESI Protocol, the court granted, in part, and denied, in part, a motion to compel plaintiff to designate additional custodians in Phase I discovery. Early on, the court bifurcated discovery. 2025 WL 1100047 (D. 15, 2025), is an exceedingly complex case. Fed.R.Civ.P.

Discovery 130
article thumbnail

Eleventh Circuit Upholds Sanctions in Energy Drink Dispute for Failure to Provide Computation of Damages

IP Watchdog

Court of Appeals for the Eleventh Circuit affirmed a district court’s ruling against Vital Pharmaceuticals, Inc. VPX) in the form of sanctions for violating its discovery obligations in a trade dress dispute with Monster Energy Company. On Wednesday, August 3, the U.S.

article thumbnail

NIH Tech Transfer Workshop Underscores Fight to Properly Characterize Federal Drug Pricing Authority

IP Watchdog

On July 31, the National Institutes of Health (NIH) hosted a virtual workshop titled Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.